Abstract
Summary
The global BTK Inhibitor market size is projected to grow from US$ 866.7 million in 2022 to US$ 1834.6 million in 2029; it is expected to grow at a CAGR of 11.3% from 2023 to 2029.
United States market for BTK Inhibitor is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for BTK Inhibitor is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for BTK Inhibitor is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key BTK Inhibitor players cover Pfizer, Aptose Eiosciences, BeiGene, Hanmi Phamaceutical, Eli Lilly, Merck, Ono Phamaceutical, AbbVie and Zhejiang DTRM Biopharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Bruton's tyrosine kinase (abbreviated Btk or BTK), also known as tyrosine-protein kinase BTK, is a tyrosine kinase that is encoded by the BTK gene in humans. BTK plays a crucial role in B cell development. Currently, BTK inhibitors are mainly applied in the treatments of hematological malignancies.
LPI (LP Information)' newest research report, the “BTK Inhibitor Industry Forecast” looks at past sales and reviews total world BTK Inhibitor sales in 2022, providing a comprehensive analysis by region and market sector of projected BTK Inhibitor sales for 2023 through 2029. With BTK Inhibitor sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world BTK Inhibitor industry.
This Insight Report provides a comprehensive analysis of the global BTK Inhibitor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on BTK Inhibitor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global BTK Inhibitor market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for BTK Inhibitor and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global BTK Inhibitor.
This report presents a comprehensive overview, market shares, and growth opportunities of BTK Inhibitor market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Tablet
Capsule
Segmentation by application
Chronic Lymphocytic Leukemia (CLL)
Follicular Lymphoma
Mantle Cell Lymphoma
Waldenstrom Macroglobulinemia
Other Selective B Cell Malignancies
Chronic Graft-versus-host Disease
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Aptose Eiosciences
BeiGene
Hanmi Phamaceutical
Eli Lilly
Merck
Ono Phamaceutical
AbbVie
Zhejiang DTRM Biopharma
AstraZeneca
Biogen
Key Questions Addressed in this Report
What is the 10-year outlook for the global BTK Inhibitor market?
What factors are driving BTK Inhibitor market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do BTK Inhibitor market opportunities vary by end market size?
How does BTK Inhibitor break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
United States market for BTK Inhibitor is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for BTK Inhibitor is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for BTK Inhibitor is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key BTK Inhibitor players cover Pfizer, Aptose Eiosciences, BeiGene, Hanmi Phamaceutical, Eli Lilly, Merck, Ono Phamaceutical, AbbVie and Zhejiang DTRM Biopharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Bruton's tyrosine kinase (abbreviated Btk or BTK), also known as tyrosine-protein kinase BTK, is a tyrosine kinase that is encoded by the BTK gene in humans. BTK plays a crucial role in B cell development. Currently, BTK inhibitors are mainly applied in the treatments of hematological malignancies.
LPI (LP Information)' newest research report, the “BTK Inhibitor Industry Forecast” looks at past sales and reviews total world BTK Inhibitor sales in 2022, providing a comprehensive analysis by region and market sector of projected BTK Inhibitor sales for 2023 through 2029. With BTK Inhibitor sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world BTK Inhibitor industry.
This Insight Report provides a comprehensive analysis of the global BTK Inhibitor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on BTK Inhibitor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global BTK Inhibitor market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for BTK Inhibitor and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global BTK Inhibitor.
This report presents a comprehensive overview, market shares, and growth opportunities of BTK Inhibitor market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Tablet
Capsule
Segmentation by application
Chronic Lymphocytic Leukemia (CLL)
Follicular Lymphoma
Mantle Cell Lymphoma
Waldenstrom Macroglobulinemia
Other Selective B Cell Malignancies
Chronic Graft-versus-host Disease
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Aptose Eiosciences
BeiGene
Hanmi Phamaceutical
Eli Lilly
Merck
Ono Phamaceutical
AbbVie
Zhejiang DTRM Biopharma
AstraZeneca
Biogen
Key Questions Addressed in this Report
What is the 10-year outlook for the global BTK Inhibitor market?
What factors are driving BTK Inhibitor market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do BTK Inhibitor market opportunities vary by end market size?
How does BTK Inhibitor break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global BTK Inhibitor Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for BTK Inhibitor by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for BTK Inhibitor by Country/Region, 2018, 2022 & 2029
2.2 BTK Inhibitor Segment by Type
2.2.1 Tablet
2.2.2 Capsule
2.3 BTK Inhibitor Sales by Type
2.3.1 Global BTK Inhibitor Sales Market Share by Type (2018-2023)
2.3.2 Global BTK Inhibitor Revenue and Market Share by Type (2018-2023)
2.3.3 Global BTK Inhibitor Sale Price by Type (2018-2023)
2.4 BTK Inhibitor Segment by Application
2.4.1 Chronic Lymphocytic Leukemia (CLL)
2.4.2 Follicular Lymphoma
2.4.3 Mantle Cell Lymphoma
2.4.4 Waldenstrom Macroglobulinemia
2.4.5 Other Selective B Cell Malignancies
2.4.6 Chronic Graft-versus-host Disease
2.4.7 Others
2.5 BTK Inhibitor Sales by Application
2.5.1 Global BTK Inhibitor Sale Market Share by Application (2018-2023)
2.5.2 Global BTK Inhibitor Revenue and Market Share by Application (2018-2023)
2.5.3 Global BTK Inhibitor Sale Price by Application (2018-2023)
3 Global BTK Inhibitor by Company
3.1 Global BTK Inhibitor Breakdown Data by Company
3.1.1 Global BTK Inhibitor Annual Sales by Company (2018-2023)
3.1.2 Global BTK Inhibitor Sales Market Share by Company (2018-2023)
3.2 Global BTK Inhibitor Annual Revenue by Company (2018-2023)
3.2.1 Global BTK Inhibitor Revenue by Company (2018-2023)
3.2.2 Global BTK Inhibitor Revenue Market Share by Company (2018-2023)
3.3 Global BTK Inhibitor Sale Price by Company
3.4 Key Manufacturers BTK Inhibitor Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers BTK Inhibitor Product Location Distribution
3.4.2 Players BTK Inhibitor Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for BTK Inhibitor by Geographic Region
4.1 World Historic BTK Inhibitor Market Size by Geographic Region (2018-2023)
4.1.1 Global BTK Inhibitor Annual Sales by Geographic Region (2018-2023)
4.1.2 Global BTK Inhibitor Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic BTK Inhibitor Market Size by Country/Region (2018-2023)
4.2.1 Global BTK Inhibitor Annual Sales by Country/Region (2018-2023)
4.2.2 Global BTK Inhibitor Annual Revenue by Country/Region (2018-2023)
4.3 Americas BTK Inhibitor Sales Growth
4.4 APAC BTK Inhibitor Sales Growth
4.5 Europe BTK Inhibitor Sales Growth
4.6 Middle East & Africa BTK Inhibitor Sales Growth
5 Americas
5.1 Americas BTK Inhibitor Sales by Country
5.1.1 Americas BTK Inhibitor Sales by Country (2018-2023)
5.1.2 Americas BTK Inhibitor Revenue by Country (2018-2023)
5.2 Americas BTK Inhibitor Sales by Type
5.3 Americas BTK Inhibitor Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC BTK Inhibitor Sales by Region
6.1.1 APAC BTK Inhibitor Sales by Region (2018-2023)
6.1.2 APAC BTK Inhibitor Revenue by Region (2018-2023)
6.2 APAC BTK Inhibitor Sales by Type
6.3 APAC BTK Inhibitor Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe BTK Inhibitor by Country
7.1.1 Europe BTK Inhibitor Sales by Country (2018-2023)
7.1.2 Europe BTK Inhibitor Revenue by Country (2018-2023)
7.2 Europe BTK Inhibitor Sales by Type
7.3 Europe BTK Inhibitor Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa BTK Inhibitor by Country
8.1.1 Middle East & Africa BTK Inhibitor Sales by Country (2018-2023)
8.1.2 Middle East & Africa BTK Inhibitor Revenue by Country (2018-2023)
8.2 Middle East & Africa BTK Inhibitor Sales by Type
8.3 Middle East & Africa BTK Inhibitor Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of BTK Inhibitor
10.3 Manufacturing Process Analysis of BTK Inhibitor
10.4 Industry Chain Structure of BTK Inhibitor
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 BTK Inhibitor Distributors
11.3 BTK Inhibitor Customer
12 World Forecast Review for BTK Inhibitor by Geographic Region
12.1 Global BTK Inhibitor Market Size Forecast by Region
12.1.1 Global BTK Inhibitor Forecast by Region (2024-2029)
12.1.2 Global BTK Inhibitor Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global BTK Inhibitor Forecast by Type
12.7 Global BTK Inhibitor Forecast by Application
13 Key Players Analysis
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer BTK Inhibitor Product Portfolios and Specifications
13.1.3 Pfizer BTK Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Aptose Eiosciences
13.2.1 Aptose Eiosciences Company Information
13.2.2 Aptose Eiosciences BTK Inhibitor Product Portfolios and Specifications
13.2.3 Aptose Eiosciences BTK Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Aptose Eiosciences Main Business Overview
13.2.5 Aptose Eiosciences Latest Developments
13.3 BeiGene
13.3.1 BeiGene Company Information
13.3.2 BeiGene BTK Inhibitor Product Portfolios and Specifications
13.3.3 BeiGene BTK Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 BeiGene Main Business Overview
13.3.5 BeiGene Latest Developments
13.4 Hanmi Phamaceutical
13.4.1 Hanmi Phamaceutical Company Information
13.4.2 Hanmi Phamaceutical BTK Inhibitor Product Portfolios and Specifications
13.4.3 Hanmi Phamaceutical BTK Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Hanmi Phamaceutical Main Business Overview
13.4.5 Hanmi Phamaceutical Latest Developments
13.5 Eli Lilly
13.5.1 Eli Lilly Company Information
13.5.2 Eli Lilly BTK Inhibitor Product Portfolios and Specifications
13.5.3 Eli Lilly BTK Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Eli Lilly Main Business Overview
13.5.5 Eli Lilly Latest Developments
13.6 Merck
13.6.1 Merck Company Information
13.6.2 Merck BTK Inhibitor Product Portfolios and Specifications
13.6.3 Merck BTK Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Merck Main Business Overview
13.6.5 Merck Latest Developments
13.7 Ono Phamaceutical
13.7.1 Ono Phamaceutical Company Information
13.7.2 Ono Phamaceutical BTK Inhibitor Product Portfolios and Specifications
13.7.3 Ono Phamaceutical BTK Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Ono Phamaceutical Main Business Overview
13.7.5 Ono Phamaceutical Latest Developments
13.8 AbbVie
13.8.1 AbbVie Company Information
13.8.2 AbbVie BTK Inhibitor Product Portfolios and Specifications
13.8.3 AbbVie BTK Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 AbbVie Main Business Overview
13.8.5 AbbVie Latest Developments
13.9 Zhejiang DTRM Biopharma
13.9.1 Zhejiang DTRM Biopharma Company Information
13.9.2 Zhejiang DTRM Biopharma BTK Inhibitor Product Portfolios and Specifications
13.9.3 Zhejiang DTRM Biopharma BTK Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Zhejiang DTRM Biopharma Main Business Overview
13.9.5 Zhejiang DTRM Biopharma Latest Developments
13.10 AstraZeneca
13.10.1 AstraZeneca Company Information
13.10.2 AstraZeneca BTK Inhibitor Product Portfolios and Specifications
13.10.3 AstraZeneca BTK Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 AstraZeneca Main Business Overview
13.10.5 AstraZeneca Latest Developments
13.11 Biogen
13.11.1 Biogen Company Information
13.11.2 Biogen BTK Inhibitor Product Portfolios and Specifications
13.11.3 Biogen BTK Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Biogen Main Business Overview
13.11.5 Biogen Latest Developments
14 Research Findings and Conclusion